

RADPHARM Case Presentation Award Rules

(Reviewed March 1999; Revised June 2008; Approved 10th July 2008)

1. The **RADPHARM Technologist Case Presentation Award**, hereafter termed the **Award**, will be held in conjunction with the Annual Scientific Meeting (ASM) of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM), hereafter termed the Society.

2. Entries to the Award will be Nuclear Technologists employed within the field of Nuclear Medicine. Such entries will have been financial members of the Society for at least 6 months at the time of presentation at the ANZSNM ASM. Students undertaking an approved course of study in Nuclear Medicine are eligible to enter.

3. The Award will be made for an **Oral Case Presentation of a single (One (1)) patient's study(s) performed within the Nuclear Medicine workplace.**

4. The Award comprises two (2) parts. An initial **Sponsorship** (part 1) will be made to the winning entrant in the Home State. The **Award** (Part 2) will be made at the Technologist Symposium of the ASM.

4.1 Previous State Winners may submit and present further case studies, however, they will be ineligible to become the State Winning Entrant for a period of two years.

5. Entrants to Part 1 and Part 2 of the Award must present their case study in the same year, the case unchanged in the intervening period.

6. PART I. Sponsorship

6.1 Entries for the Award are to present an oral case study in their Home State or in New Zealand (NZ) or at a pre-arranged Rural site. The *Home State/NZ/Rural* site shall be the region in which:

- a) the entrant is employed/studying in the field of Nuclear Medicine and,
- b) where the case study was obtained.

6.2 The Home States in Australia shall be deemed one of the following:

- a) NSW
- b) QLD
- c) SA (including NT)
- d) ACT
- e) VIC (including Tasmania)
- f) WA

6.3 The **Rural entrant must fulfil one (1) of the following eligibility criteria:**

- a) employed in a department in an RRMA (Rural Remote Metropolitan Area) classified rural or remote area (see Appendix A)
- b) a department more than 200km from their state capital
- c) a department more than 100km from any other Nuclear Medicine Department
- d) a department more than 200km from their relevant branch meeting.

6.4 Entrants to the Award are to present to the State/NZ Branch representative of the ANZSNM Technologist Group (ANZSNMT) a signed statement, countersigned by the department head indicating the extent of assistance received during the course of the case study work. In the case of a video presentation this statement should also confirm that the presentation was performed in accordance with the Rules and that the video has not been edited.

6.5 The winner of the State/NZ/Rural sponsoring will be required to provide this statement to the Hon. Secretary ANZSNMT on submission of the abstract to Part 2 of the Award.

6.6 Entrants to the Award {Part I and 2}, are to present their case study in a maximum of ten (10) minutes. The total presentation time will be divided as:

- a) oral case presentation -7 minutes (maximum)
- b) question time -3 minutes (maximum)

6.7 The State Branch/NZ Branch representative of the ANZSNMT will organise a venue and time for the presentation of case by entries to the Award, in the year prior to the ASM of the Society each year. Entrants to the Award who are normally located remotely from the presentation venue may submit a video presentation, performed before an audience of professional healthcare colleagues, to be viewed by the audience and judges at the presentation meeting. The current entrant will be available via telephone link to answer questions from the presentation meeting.

6.8 Judges for the State/NZ sponsorships shall determine the winning case presentation. The home State/NZ/Rural entrant awarded the sponsorship shall be termed a National or NZ finalist.

6.9 The State/NZ/Rural sponsorships shall be Judged by a panel of three (3) Nuclear Medicine Technologists. The panel will be nominated by the State Branch representative of the ANZSNMT. The panel must include the nominated State representative of the ANZSNMT. All panel members are to be full financial members of the Society, and eligible for accreditation. Where possible the judging panel should not be drawn from the same workplace/department as any entry to the award.

6.10 If there is only one case presentation within a State/NZ/Rural, the case study must be presented to a panel of three (3) Nuclear Medicine Technologists at a presentation night or Branch meeting. The panel of judges must judge whether the presentation is worthy and hence eligible for the Sponsorship. If judged to be unworthy, there will be no winner from that Home State or NZ.

6.11 The National and NZ finalist will be sponsored by RADPHARM/GMS for full registration to attend the Technologist Symposium of the ASM, to present their winning case study. Winners of Part 1 Sponsorship are the only entrant to Part 2 of the Award.

7. PART 2 The Award

7.1 National and NZ finalists must submit an abstract of their winning case presentation for the Technologist Symposium as with any paper. Submission of abstract must be in accordance with the requirements of the ASM.

7.2 The audience will be informed that the presentation is an entry for the **RADPHARM Technologist Case Presentation Award**

7.3 The Award will be judged by a panel of seven (7) Nuclear Medicine Technologist representatives, each nominated by their State/NZ Branch representative of the ANZSNMT. The judging panel must not be drawn from the same department/workplace as entry to the Award.

8. The Sponsorship and the Award will be decided on the following criteria with value specified,

- a) - Originality
- b) - Presentation
- c) - Content (Correlative Investigations may be used.)
- d) - Interest/Value of paper to Nuclear Medicine
- e) - Contribution of Nuclear Medicine to patient management.

9. The **RADPHARM Technologist Case Presentation Award** will be presented at the conclusion of the Conference.

10. The recipient of the Award should provide to the ANZSNMT Honorary Secretary, an appropriate summary of the case study presentation for publication in the ANZSNM Journal.

APPENDIX A:

The Rural, Remote and Metropolitan Area (RRMA) classification was developed in 1994 by the Department of Primary Industries and Energy, and the then Department of Human Services and Health, which is now the Australian Institute of Health and Welfare. ⁽¹⁾

Seven (7) categories are included in this classification – 2 metropolitan, 3 rural and 2 remote. The classification is based on Statistical Local Areas (SLA) and allocates each SLA in Australia to a category based primarily on population numbers and an index of remoteness. The index is used to allocate non-metropolitan SLAs to either the rural or remote zone.

Zone	Category
Metropolitan zone	M1 Capital cities
	M2 Other metropolitan centres (urban population > 100,000)
Rural zone	R1 Large rural centres (urban centre population 25,000 – 99,999)
	R2 Small rural centres (urban centre population 10,000 – 24,999)
	R3 Other rural areas (urban centre population < 10,000)
Remote zone	Rem1 Remote centres (urban centre population > 4,999)
	Rem2 Other remote areas (urban centre population < 5,000)

The RADPHARM award eligibility criteria refers only to the Rural and remote classification zones.

Reference:

1. <http://www.aihw.gov.au/ruralhealth/methodology/rrma.cfm>